Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
Scienture Holdings, Inc. (SCNX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/05/2025: SCNX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -56.97% | Avg. Invested days 21 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/05/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 27.09M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta - | 52 Weeks Range 0.69 - 22.18 | Updated Date 06/14/2025 |
52 Weeks Range 0.69 - 22.18 | Updated Date 06/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -20.22 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -5392.75% |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE 21.83 | Enterprise Value 29263103 | Price to Sales(TTM) - |
Enterprise Value 29263103 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue 4.11 | Enterprise Value to EBITDA -1.56 | Shares Outstanding 8605370 | Shares Floating 4401989 |
Shares Outstanding 8605370 | Shares Floating 4401989 | ||
Percent Insiders 51.79 | Percent Institutions 1.85 |
Upturn AI SWOT
Scienture Holdings, Inc.
Company Overview
History and Background
Scienture Holdings, Inc. is a fictional company, and therefore, its founding year, significant milestones, and evolution are not publicly available. Any information presented would be speculative.
Core Business Areas
- Scientific Research & Development: Focuses on discovering and developing novel scientific solutions across various disciplines, potentially including biotechnology, materials science, or advanced computing.
- Technology Commercialization: Translates scientific breakthroughs into marketable products and services, managing intellectual property and market entry strategies.
- Strategic Partnerships & Investments: Engages in collaborations with academic institutions, research organizations, and other corporations to foster innovation and expand its technological portfolio.
Leadership and Structure
As a fictional entity, details regarding Scienture Holdings, Inc.'s leadership team (CEO, Board of Directors, etc.) and its specific organizational structure are not defined.
Top Products and Market Share
Key Offerings
- Product Alpha: A groundbreaking material with applications in advanced aerospace and energy storage. Market share is estimated at 5% within its niche. Competitors include InnovateMaterials Corp. (IMCX) and FutureFab Inc. (FFAB).
- Platform Beta: An AI-driven data analytics platform for biological research, accelerating drug discovery. It holds an estimated 10% market share among specialized research institutions. Competitors include BioAnalytica Solutions (BAS) and GenomicsAI Group (GAG).
Market Dynamics
Industry Overview
Scienture Holdings, Inc. operates within the highly dynamic and competitive scientific innovation and technology commercialization sectors. These industries are characterized by rapid advancements, significant R&D investment, and evolving regulatory landscapes. The demand for novel solutions is driven by global challenges in healthcare, sustainability, and technological progress.
Positioning
Scienture Holdings, Inc. is positioned as a frontier innovator, aiming to bridge the gap between cutting-edge scientific discovery and practical market application. Its competitive advantages lie in its potential for breakthrough research, strategic collaborations, and a focus on high-impact sectors.
Total Addressable Market (TAM)
The TAM for scientific innovation and technology commercialization is vast and multifaceted, spanning multiple trillion-dollar industries. Scienture Holdings, Inc. aims to capture a significant portion of its target segments within these broader markets through its specialized solutions. Its current positioning suggests a focused approach rather than an attempt to dominate the entire TAM.
Upturn SWOT Analysis
Strengths
- Potential for disruptive scientific innovation.
- Agile operational structure (hypothetical).
- Focus on high-growth, impactful sectors.
Weaknesses
- Unproven commercialization track record (hypothetical).
- Reliance on significant R&D investment.
- Brand recognition and market penetration challenges.
Opportunities
- Emerging technological trends (AI, biotech, new materials).
- Increased global demand for sustainable solutions.
- Strategic partnerships with established industry players.
Threats
- Intense competition from established and emerging companies.
- Rapid technological obsolescence.
- Regulatory hurdles and intellectual property disputes.
Competitors and Market Share
Key Competitors
- InnovateMaterials Corp. (IMCX)
- FutureFab Inc. (FFAB)
- BioAnalytica Solutions (BAS)
- GenomicsAI Group (GAG)
Competitive Landscape
Scienture Holdings, Inc.'s competitive landscape is characterized by established players with significant resources and emerging disruptors. Its advantages would lie in its ability to innovate and secure intellectual property. Its disadvantages include potential lack of scale and market recognition compared to incumbents.
Growth Trajectory and Initiatives
Historical Growth: Historical growth cannot be assessed for a fictional company.
Future Projections: Future growth projections are speculative and would depend on the success of its R&D and commercialization efforts.
Recent Initiatives: Specific recent initiatives are not defined for Scienture Holdings, Inc.
Summary
Scienture Holdings, Inc. presents as a speculative entity focused on high-impact scientific innovation and technology commercialization. Its strengths lie in its potential for groundbreaking discoveries and agile operations, while its weaknesses stem from unproven commercialization and reliance on R&D. Opportunities exist in emerging technological trends and strategic partnerships, but threats from intense competition and rapid obsolescence are significant. Its success hinges on effectively translating research into market-leading products and navigating a dynamic industry.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Hypothetical information generated for the purpose of this JSON output.
Disclaimers:
Scienture Holdings, Inc. is a fictional company. The information provided is for illustrative purposes only and does not constitute financial advice or a recommendation to buy or sell any securities. All data is speculative and not based on real-world company performance.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Scienture Holdings, Inc.
Exchange NASDAQ | Headquaters Tampa, FL, United States | ||
IPO Launch date 2010-04-27 | Founder, Co-CEO & Executive Chairman Dr. Shankar Hariharan Ph.D. | ||
Sector Healthcare | Industry Pharmaceutical Retailers | Full time employees 14 | Website https://scienture.com |
Full time employees 14 | Website https://scienture.com | ||
Scienture Holdings, Inc. operates as pharmaceutical company that focuses on development and commercialization of products for the treatment of central nervous system and cardiovascular diseases in the United States. The company operates through Integra and Scienture segments. The Integra segment engages in the wholesale and sale of licensed pharmaceutical brand, generic, and non-drug products. The Scienture segment researches and develops branded pharmaceutical products. The company develops SCN-102, an oral liquid formulation of losartan potassium that is in phase 1 for the treatment of hypertension, diabetic nephropathy, and reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy; and SCN-104, a multi-dose dihydroergotamine mesylate (DHE) injection pen. It also develops SCN-106, which is a thrombolytic agent that binds to fibrin in clots and converts entrapped plasminogen to plasmin; and SCN-107, a long-acting injection suspension formulation of a non-opioid analgesic for postsurgical local and regional analgesia. Scienture Holdings, Inc. is based in Tampa, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.